Posted by Michael Wonder on 19 Jul 2022
TGA provisionally approves Moderna COVID-19 vaccine (Spikevax) for use in children from 6 months
19 July 2022 - The TGA has provisionally approved a paediatric dose of the Moderna COVID-19 vaccine, Spikevax, for use in individuals aged 6 months to less than 6 years (6 months to 5 years).
Currently this mRNA vaccine is provisionally approved for immunisation to prevent COVID-19 in individuals aged 6 years and older (primary series of 2 doses administered at least 28 days apart), and as a booster dose for adults aged 18 years and older. As we have seen with children in older age groups, the TGA expects that vaccines for younger children will provide protection from the most severe outcomes of COVID-19, such as hospitalisation and death.
